NCT00556062View on ClinicalTrials.gov

Phase IV Clinical Trial of an Influenza Split Vaccine Anflu

PHASE4CompletedINTERVENTIONAL
Enrollment

566

Participants

Timeline

Start Date

September 30, 2007

Study Completion Date

November 30, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

seasonal split influenza vaccine

0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime

BIOLOGICAL

seasonal split influenza vaccine

0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime

BIOLOGICAL

seasonal split influenza vaccine

0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime

BIOLOGICAL

seasonal split influenza vaccine

0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT00556062 - Phase IV Clinical Trial of an Influenza Split Vaccine Anflu | Biotech Hunter | Biotech Hunter